These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 16258274)

  • 1. A novel role of p38 alpha MAPK in mitotic progression independent of its kinase activity.
    Fan L; Yang X; Du J; Marshall M; Blanchard K; Ye X
    Cell Cycle; 2005 Nov; 4(11):1616-24. PubMed ID: 16258274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclin B1 proteolysis via p38 MAPK signaling participates in G2 checkpoint elicited by arsenite.
    Li JP; Yang JL
    J Cell Physiol; 2007 Aug; 212(2):481-8. PubMed ID: 17373649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of mixed-lineage kinase (MLK) activity during G2-phase disrupts microtubule formation and mitotic progression in HeLa cells.
    Cha H; Dangi S; Machamer CE; Shapiro P
    Cell Signal; 2006 Jan; 18(1):93-104. PubMed ID: 15923109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p38alpha and p38delta mitogen-activated protein kinase isoforms regulate invasion and growth of head and neck squamous carcinoma cells.
    Junttila MR; Ala-Aho R; Jokilehto T; Peltonen J; Kallajoki M; Grenman R; Jaakkola P; Westermarck J; Kähäri VM
    Oncogene; 2007 Aug; 26(36):5267-79. PubMed ID: 17334397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular modeling of p38α mitogen-activated protein kinase inhibitors through 3D-QSAR and molecular dynamics simulations.
    Chang HW; Chung FS; Yang CN
    J Chem Inf Model; 2013 Jul; 53(7):1775-86. PubMed ID: 23808966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential roles of JNK, ERK1/2, and p38 mitogen-activated protein kinases on endothelial cell tissue repair functions in response to tumor necrosis factor-α.
    Kanaji N; Nelson A; Wang X; Sato T; Nakanishi M; Gunji Y; Basma H; Michalski J; Farid M; Rennard SI; Liu X
    J Vasc Res; 2013; 50(2):145-56. PubMed ID: 23258237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Comprehensive Structural Overview of p38α MAPK in Complex with Type I Inhibitors.
    Astolfi A; Iraci N; Manfroni G; Barreca ML; Cecchetti V
    ChemMedChem; 2015 Jun; 10(6):957-69. PubMed ID: 26012502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The antiapoptotic effect of heme oxygenase-1 in endothelial cells involves the degradation of p38 alpha MAPK isoform.
    Silva G; Cunha A; Grégoire IP; Seldon MP; Soares MP
    J Immunol; 2006 Aug; 177(3):1894-903. PubMed ID: 16849502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p38α MAPK and Type I Inhibitors: Binding Site Analysis and Use of Target Ensembles in Virtual Screening.
    Astolfi A; Iraci N; Sabatini S; Barreca ML; Cecchetti V
    Molecules; 2015 Aug; 20(9):15842-61. PubMed ID: 26334265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Catalysis and function of the p38 alpha.MK2a signaling complex.
    Lukas SM; Kroe RR; Wildeson J; Peet GW; Frego L; Davidson W; Ingraham RH; Pargellis CA; Labadia ME; Werneburg BG
    Biochemistry; 2004 Aug; 43(31):9950-60. PubMed ID: 15287722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective requirement of p38alpha MAPK in cytokine-dependent, but not antigen receptor-dependent, Th1 responses.
    Berenson LS; Yang J; Sleckman BP; Murphy TL; Murphy KM
    J Immunol; 2006 Apr; 176(8):4616-21. PubMed ID: 16585552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Noncatalytic Substrate-Selective p38α-Specific MAPK Inhibitors with Endothelial-Stabilizing and Anti-Inflammatory Activity.
    Shah NG; Tulapurkar ME; Ramarathnam A; Brophy A; Martinez R; Hom K; Hodges T; Samadani R; Singh IS; MacKerell AD; Shapiro P; Hasday JD
    J Immunol; 2017 Apr; 198(8):3296-3306. PubMed ID: 28298524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The p53 pathway is synergized by p38 MAPK signaling to mediate 11,11'-dideoxyverticillin-induced G2/M arrest.
    Chen Y; Miao ZH; Zhao WM; Ding J
    FEBS Lett; 2005 Jul; 579(17):3683-90. PubMed ID: 15963507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The alpha-isoform of p38 MAPK specifically regulates arthritic bone loss.
    Böhm C; Hayer S; Kilian A; Zaiss MM; Finger S; Hess A; Engelke K; Kollias G; Krönke G; Zwerina J; Schett G; David JP
    J Immunol; 2009 Nov; 183(9):5938-47. PubMed ID: 19828631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon-alpha induces the growth inhibition of human T-cell leukaemia line Jurkat through p38alpha and p38beta.
    Lee WH; Liu FH; Lee YL; Huang HM
    J Biochem; 2010 May; 147(5):645-50. PubMed ID: 20053787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and molecular docking study of new benzofuran and furo[3,2-g]chromone-based cytotoxic agents against breast cancer and p38α MAP kinase inhibitors.
    Amin KM; Syam YM; Anwar MM; Ali HI; Abdel-Ghani TM; Serry AM
    Bioorg Chem; 2018 Feb; 76():487-500. PubMed ID: 29310080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, Synthesis, and Molecular Docking of Novel Miscellaneous Chalcones as p38α Mitogen-Activated Protein Kinase Inhibitors.
    Zeid MM; El-Badry OM; Elmeligie S; Hassan RA
    Chem Biodivers; 2024 Apr; 21(4):e202400077. PubMed ID: 38359316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic deficiency of p38alpha reveals its critical role in myoblast cell cycle exit: the p38alpha-JNK connection.
    Perdiguero E; Ruiz-Bonilla V; Serrano AL; Muñoz-Cánoves P
    Cell Cycle; 2007 Jun; 6(11):1298-303. PubMed ID: 17534150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of p38alpha mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma.
    Vanderkerken K; Medicherla S; Coulton L; De Raeve H; Willems A; Lawson M; Van Camp B; Protter AA; Higgins LS; Menu E; Croucher PI
    Cancer Res; 2007 May; 67(10):4572-7. PubMed ID: 17495322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Stress Kinase p38α as a Target for Cancer Therapy.
    Igea A; Nebreda AR
    Cancer Res; 2015 Oct; 75(19):3997-4002. PubMed ID: 26377941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.